Drug Classes & How They Work
- Mealtime insulins are categorized into ultra-rapid-acting formulations, rapid-acting insulin analogs, and short-acting regular human insulin (1.1) (2.1) (4.1).
| Mealtime Insulin Subtype | Active Ingredient & Trade Examples | Onset & Peak Action | Duration & Pre-Meal Timing |
|---|---|---|---|
| Ultra-rapid-acting aspart | Insulin aspart + niacinamide (Fiasp) | Onset 2.5-15 min; peak 1-2 hr | 3-5 hr duration; dosed at the start of a meal or within 20 minutes after starting to eat (2.1) (3.1) |
| Rapid-acting insulin lispro | Insulin lispro (Humalog, Admelog) | Onset 15-30 min; peak 1-2.5 hr | 3-5 hr duration; dosed within 15 minutes before a meal or immediately after eating (1.1) (2.1) |
| Rapid-acting insulin aspart | Insulin aspart (NovoLog / NovoRapid, Trurapi) | Onset 10-20 min; peak 1-3 hr | 3-5 hr duration; dosed 5 to 10 minutes before a meal or used in CSII insulin pumps (1.1) (2.1) |
| Rapid-acting insulin glulisine | Insulin glulisine (Apidra) | Onset 15-20 min; peak 1-2 hr | 3-4 hr duration; zinc-free formulation dosed within 15 minutes before or 20 minutes after starting a meal (2.1) (4.1) |
| Short-acting regular human insulin | Regular insulin rDNA (Humulin R, Novolin ge Toronto) | Onset 30-60 min; peak 2-4 hr | 6-8 hr duration; must be injected 30 minutes prior to eating to align peak action with meal absorption (1.1) (2.1) |
Fast-acting insulin: Clinical Overview & Scope
Fast-acting (prandial or bolus) insulins are engineered to replicate the physiological first-phase insulin surge secreted by healthy pancreatic beta cells in response to carbohydrate absorption during meals (1.1) (2.1).
In unmodified regular human insulin, individual insulin molecules self-associate around zinc ions into six-molecule clusters (hexamers) in the subcutaneous tissue, delaying capillary absorption for 30 to 60 minutes (2.1) (3.1).
Rapid-acting insulin analogs, insulin lispro, insulin aspart, and insulin glulisine, modify one or two amino acids on the B-chain to destabilize hexamer formation, allowing immediate dissociation into monomers that enter the bloodstream within 10 to 20 minutes of injection (1.1) (2.1).
Representative medications in our fast-acting insulin directory include Apidra (Insulin Glulisine), Fiasp (Insulin Aspart), Humalog (Insulin Lispro), Novolog (Insulin Aspart), Novorapid Penfill (Insulin Aspart), Kirsty (Insulin Aspart) (1.1).
Dosage Forms, Release Profiles & Devices
- Rapid-acting mealtime insulins are clear, colorless aqueous solutions available in 10 mL U-100 vials, 3 mL cartridges (PenFill / Humalog cartridges), and 3 mL prefilled disposable pens (KwikPen, Junior KwikPen with 0.5-unit increments, FlexTouch, FlexPen, and SoloStar) (2.1) (4.1).
- In continuous subcutaneous insulin infusion (CSII) external insulin pumps, rapid-acting analogs (lispro, aspart, glulisine) are the standard of care; insulin in a pump reservoir must be changed according to the specific manufacturer schedule (typically every 48 to 72 hours, or earlier if exposed to temperatures above 37°C/98.6°F) to prevent fibril precipitation and catheter occlusion (1.1) (2.1).
- Note that Canadian NovoRapid and U.S. NovoLog are manufactured by Novo Nordisk with the identical active ingredient (insulin aspart rDNA 100 units/mL), and Novolin ge Toronto is the Canadian trade name for short-acting regular human insulin (Novolin R) (2.1) (4.1).
Key Safety, Storage & Monitoring Points
- Because rapid-acting analogs begin lowering blood glucose within 15 minutes of injection, patients must have their meal ready to eat before injecting; injecting a rapid-acting insulin and then delaying or skipping food intake will precipitate acute post-injection hypoglycemia (1.1) (2.1).
- Conversely, short-acting regular human insulin (Humulin R / Novolin ge Toronto) has a slower 30-to-60-minute onset and a longer 6-to-8-hour tail, which increases the risk of late postprandial hypoglycemia between meals if doses are "stacked" too closely together (1.1) (3.1).
- Fast-acting insulins must always be visually inspected before each injection: the liquid must be crystal clear and colorless, and any vial or pen showing cloudiness, clumping, frosting, or discoloration must be discarded (2.1).
Ordering & Prescription Checklist for U.S. Patients
- Match your prescription details: Confirm the active ingredient name, exact milligram or microgram strength, release profile, and package quantity on your U.S. prescription (2.1) (4.1).
- Licensed pharmacist review: Every order undergoes a dosing, strength, and drug-interaction check in under 1 business day, followed by a mandatory pharmacist consultation before dispatch (3.1).
- Transparent USD pricing and shipping: Room-temperature medications ship for $14.99 USD flat rate and cold-chain medications ship in $29.99 USD insulated coolers via tracked Canada Post and USPS delivery.
- Need help matching a product or transferring an Rx? Call 1-888-868-1920 (Monday - Friday: 9:00AM - 6:00PM; Saturday - Sunday: Closed) or review our step-by-step ordering guide and prescription requirements.
Frequently Asked Questions
Are NovoRapid and NovoLog the exact same insulin?
How does Fiasp differ from standard NovoRapid / NovoLog (insulin aspart)?
Fiasp contains the same active molecule (insulin aspart) but adds niacinamide (vitamin B3) to accelerate initial subcutaneous absorption across capillary membranes, plus L-arginine as a stabilizer (2.1) (3.1). This allows Fiasp to appear in the bloodstream within ~2.5 minutes and be injected right at the start of a meal.
What is "insulin stacking" with fast-acting mealtime insulin?
Rapid-acting insulin continues working for 3 to 5 hours after an injection (and regular human insulin lasts 6 to 8 hours) (1.1) (2.1). Taking a second full correction dose within 2 hours of a previous mealtime injection, before the first dose has finished working, causes the two doses to overlap ("stack") and can trigger severe hypoglycemia.
Related Medical Conditions
Related Practical Comparison Guides
References & Official Clinical Sources
Pharmacological classifications, mechanism comparisons, dosing-form distinctions, and clinical safety notes for fast-acting insulin are compiled from official regulatory prescribing monographs and medical practice guidelines:
- (1.1) Standards of Care in Diabetes (2024): Pharmacologic Approaches to Glycemic Treatment, American Diabetes Association (Diabetes Care).
- (2.1) DailyMed: FDA Prescribing Information for Humalog, NovoLog, Fiasp, Apidra, and Humulin R, U.S. National Library of Medicine / FDA.
- (3.1) Pharmacokinetics and Pharmacodynamics of Rapid-Acting Insulin Analogs, Endotext / National Center for Biotechnology Information (NIH).
- (4.1) Health Canada Drug Product Database: Rapid-Acting Insulin Monographs, Health Canada.
Need help finding your medication? Call 1-888-868-1920.